Baxter International Inc  

(Public, NYSE:BAX)   Watch this stock  
Find more results for BAX
47.20
-0.29 (-0.61%)
After Hours: 47.20 0.00 (0.00%)
Sep 26, 4:28PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 47.01 - 47.42
52 week 32.18 - 49.49
Open 47.34
Vol / Avg. 0.00/4.21M
Mkt cap 25.29B
P/E 5.45
Div/yield 0.13/1.10
EPS 8.66
Shares 543.89M
Beta 0.64
Inst. own 88%
Oct 25, 2016
Q3 2016 Baxter International Inc Earnings Release (Estimated) Add to calendar
Sep 12, 2016
Baxter International Inc at Morgan Stanley Global Healthcare Conference
Sep 7, 2016
Baxter International Inc at Goldman Sachs Medtech Conference
Jul 26, 2016
Q2 2016 Baxter International Inc Earnings Call - Webcast
Jul 26, 2016
Q2 2016 Baxter International Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin 46.89% 3.94%
Operating margin 47.04% 5.58%
EBITD margin - 14.79%
Return on average assets 29.17% 1.68%
Return on average equity 55.47% 4.63%
Employees 50,000 -
CDP Score - 99 B

Address

One Baxter Pkwy, Df2-1W
DEERFIELD, IL 60015-4625
United States - Map
+1-847-9482000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Baxter International Inc., through its subsidiaries, provides a portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics, and pharmacy automation, software and services. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures IV solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. The business also provides products and services related to pharmacy compounding, and drug formulation. The Renal business provides products and services to treat end-stage renal disease, or irreversible kidney failure and acute kidney injuries.

Officers and directors

Jose E. Almeida Chairman of the Board, Chief Executive Officer
Age: 53
Bio & Compensation  - Reuters
James K. Saccaro Corporate Vice President and Chief Financial Officer
Age: 43
Bio & Compensation  - Reuters
Marcus Schabacker M.D. Ph.D. Chief Scientific Officer, Corporate Vice President
Age: 52
Bio & Compensation  - Reuters
David P. Scharf Corporate Vice President, General Counsel
Age: 48
Bio & Compensation  - Reuters
.. Karp Corporate Vice President, Controller
Age: 42
Bio & Compensation  - Reuters
Jeanne K. Mason Ph.D. Corporate Vice President - Human Resources
Age: 60
Bio & Compensation  - Reuters
Brik V. Eyre Corporate Vice President, President - Hospital Products
Age: 52
Bio & Compensation  - Reuters
Robert Felicelli Corporate Vice President - Quality
Age: 57
Bio & Compensation  - Reuters
Timothy P. Lawrence Corporate Vice President - Operations
Age: 53
Bio & Compensation  - Reuters
Jill M. Schaaf Corporate Vice President and President - Renal
Age: 52
Bio & Compensation  - Reuters